PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) EPS (Diluted) : $-2.13 (TTM As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals EPS (Diluted)?

PhaseBio Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $-0.34. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.13.

PhaseBio Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2022 was $-0.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.13.

PhaseBio Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2022 was $-0.52. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

PhaseBio Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for PhaseBio Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals EPS (Diluted) Chart

PhaseBio Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Diluted)

Get a 7-Day Free Trial

-13.78

-4.49

-1.43

-3.39

-2.98

PhaseBio Pharmaceuticals Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EPS (Diluted)	Get a 7-Day Free Trial															-0.60	-0.66	-0.90	-0.23	-0.34

Competitive Comparison of PhaseBio Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseBio Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's PE Ratio falls into.

PhaseBio Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

PhaseBio Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-131.071	-	0)	/	43.919
	=	-2.98

PhaseBio Pharmaceuticals's Diluted EPS for the quarter that ended in Jun. 2022 is calculated as

Diluted EPS (Q: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-16.665	-	0)	/	49.183
	=	-0.34

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.13

PhaseBio Pharmaceuticals (OTCPK:PHASQ) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

PhaseBio Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355

Website

https://www.phasebio.com

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Executives

New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt	officer: VP, Human Resources	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall	officer: Chief Commercial Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance	officer: VP, Research and Sci. Affairs	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York	officer: VP, Corporate Development	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee	officer: Chief Medical Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold	officer: VP, Preclinical and Chem	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson	officer: VP, Head of Legal	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355